Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SILVERBACK THERAPEUTICS, INC.

(SBTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Silverback Therapeutics : Reports Early Data From Phase 1/1b Study of SBT6050 in Solid Tumors; Stock Slumps

09/16/2021 | 10:57am EDT


ę MT Newswires 2021
All news about SILVERBACK THERAPEUTICS, INC.
10/05SILVERBACK THERAPEUTICS : to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Co..
BU
09/19SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silve..
PR
09/16SILVERBACK THERAPEUTICS : Reports Early Data From Phase 1/1b Study of SBT6050 in Solid Tum..
MT
09/16SILVERBACK THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
09/16SILVERBACK THERAPEUTICS : Presents Interim Clinical Results from the Ongoing Phase 1/1b St..
BU
09/16Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b S..
CI
09/14SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silve..
PR
09/13SILVERBACK THERAPEUTICS : Releases Preliminary Data From Early Solid Tumors Trial of Cell ..
MT
09/13Top Midday Decliners
MT
09/13TITLE : Results of an ongoing Phase 1/1b study of SBT6050 as monotherapy and combined with..
PU
More news
Analyst Recommendations on SILVERBACK THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -96,8 M - -
Net cash 2021 496 M - -
P/E ratio 2021 -3,26x
Yield 2021 -
Capitalization 316 M 316 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 76
Free-Float 91,6%
Chart SILVERBACK THERAPEUTICS, INC.
Duration : Period :
Silverback Therapeutics, Inc. Technical Analysis Chart | SBTX | US82835W1080 | MarketScreener
Technical analysis trends SILVERBACK THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 9,03 $
Average target price 44,25 $
Spread / Average Target 390%
EPS Revisions
Managers and Directors
Laura K. Shawver Chief Executive Officer & Director
Valerie Odegard President & Chief Scientific Officer
Jonathan Piazza Chief Financial Officer
Peter A. Thompson Chairman
Naomi Hunder Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SILVERBACK THERAPEUTICS, INC.-80.51%316
MODERNA, INC.234.60%141 099
LONZA GROUP AG31.93%60 646
IQVIA HOLDINGS INC.43.58%49 145
SEAGEN INC.0.22%31 933
CELLTRION, INC.-38.02%25 328